A New Big-Data Paradigm for Target Identification and Drug Discovery

Drug target identification is one of the most important aspects of pre-clinical development yet it is also among the most complex, labor-intensive, and costly. This represents a major issue, as lack of proper target identification can be detrimental in determining the clinical application of a bioactive small molecule. To improve target identification, we developed BANDIT, a novel paradigm that integrates multiple data types within a Bayesian machine-learning framework to predict the targets and mechanisms for small molecules with unprecedented accuracy and versatility. Using only public data BANDIT achieved an accuracy of approximately 90% over 2000 different small molecules – substantially better than any other published target identification platform. We applied BANDIT to a library of small molecules with no known targets and generated ∼4,000 novel molecule-target predictions. From this set we identified and experimentally validated a set of novel microtubule inhibitors, including three with activity on cancer cells resistant to clinically used anti-microtubule therapies. We next applied BANDIT to ONC201 – an active anti- cancer small molecule in clinical development – whose target has remained elusive since its discovery in 2009. BANDIT identified dopamine receptor 2 as the unexpected target of ONC201, a prediction that we experimentally validated. Not only does this open the door for clinical trials focused on target-based selection of patient populations, but it also represents a novel way to target GPCRs in cancer. Additionally, BANDIT identified previously undocumented connections between approved drugs with disparate indications, shedding light onto previously unexplained clinical observations and suggesting new uses of marketed drugs. Overall, BANDIT represents an efficient and highly accurate platform that can be used as a resource to accelerate drug discovery and direct the clinical application of small molecule therapeutics with improved precision.

[1]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[2]  Avi Ma'ayan,et al.  Lean Big Data integration in systems biology and systems pharmacology. , 2014, Trends in pharmacological sciences.

[3]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[4]  E. Messaris,et al.  Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.

[5]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[6]  Louiqa Raschid,et al.  Ieee/acm Transactions on Computational Biology and Bioinformatics 1 Network-based Drug-target Interaction Prediction with Probabilistic Soft Logic , 2022 .

[7]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[8]  Lin He,et al.  Prediction of Drug-Target Interactions for Drug Repositioning Only Based on Genomic Expression Similarity , 2013, PLoS Comput. Biol..

[9]  Chartchalerm Isarankura-Na-Ayudhya,et al.  Advances in computational methods to predict the biological activity of compounds , 2010, Expert opinion on drug discovery.

[10]  H. Hsieh,et al.  Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. , 2003, Biochemical pharmacology.

[11]  A. Frantz,et al.  Dopamine antagonism by thioridazine in schizophrenia. , 1975, Biological psychiatry.

[12]  D. Butina,et al.  Predicting ADME properties in silico: methods and models. , 2002, Drug discovery today.

[13]  F. Monsma,et al.  Characterizing Cannabinoid CB 2 Receptor Ligands Using DiscoveRx PathHunter™ β-Arrestin Assay , 2009, Journal of biomolecular screening.

[14]  N. Lawrence,et al.  Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle , 1998, Medicinal research reviews.

[15]  Avi Ma'ayan,et al.  Drug-induced adverse events prediction with the LINCS L1000 data , 2016, Bioinform..

[16]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[17]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[18]  R. Davis,et al.  ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition , 2014 .

[19]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[20]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[21]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[22]  C. Marsden,et al.  Effect of new dopamine-blocking agent (oxiperomide) on drug-induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. , 1978, British medical journal.

[23]  John C. Dearden,et al.  In silico prediction of drug toxicity , 2003, J. Comput. Aided Mol. Des..

[24]  Yoshihiro Yamanishi,et al.  Predicting target proteins for drug candidate compounds based on drug-induced gene expression data in a chemical structure-independent manner , 2015, BMC Medical Genomics.

[25]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[26]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[27]  Corey Nislow,et al.  Recent advances and method development for drug target identification. , 2010, Trends in pharmacological sciences.

[28]  C. Clarke,et al.  Beta-blocker therapy for tremor in Parkinson's disease. , 2003, The Cochrane database of systematic reviews.

[29]  Yongdong Zhang,et al.  Drug-target interaction prediction: databases, web servers and computational models , 2016, Briefings Bioinform..

[30]  A. Borsodi,et al.  Microtubule dissassembly increases the number of opioid receptor binding sites in rat cerebrum membranes , 1986, Neuropeptides.

[31]  Ru Zhang,et al.  Tools for GPCR drug discovery , 2012, Acta Pharmacologica Sinica.

[32]  Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area , 2014, European Journal of Clinical Pharmacology.

[33]  Hua Xu,et al.  Identifying Plausible Adverse Drug Reactions Using Knowledge Extracted from the Literature , 2014, AMIA.

[34]  Eiman Mukhtar,et al.  Targeting Microtubules by Natural Agents for Cancer Therapy , 2014, Molecular Cancer Therapeutics.

[35]  J. Weigelt The case for open‐access chemical biology , 2009, EMBO reports.

[36]  W. El-Deiry,et al.  The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity , 2014, Oncotarget.

[37]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[38]  Bin Chen,et al.  PubChem BioAssays as a data source for predictive models. , 2010, Journal of molecular graphics & modelling.

[39]  Igor Jurisica,et al.  Prioritizing Therapeutics for Lung Cancer: An Integrative Meta-analysis of Cancer Gene Signatures and Chemogenomic Data , 2015, PLoS Comput. Biol..

[40]  K. Nicolaou,et al.  Synthesis of epothilones A and B in solid and solution phase , 1997, Nature.

[41]  Roded Sharan,et al.  Combining Drug and Gene Similarity Measures for Drug-Target Elucidation , 2011, J. Comput. Biol..

[42]  Pedro Cuatrecasas,et al.  Drug discovery in jeopardy. , 2006, The Journal of clinical investigation.

[43]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[44]  J. Gerlach,et al.  Oxiperomide in tardive dyskinesia. , 1980, Journal of neurology, neurosurgery, and psychiatry.

[45]  P. Marchetti,et al.  Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study , 2014, Journal of Cancer.

[46]  T. Fojo,et al.  Tubulin/microtubules: still a promising target for new chemotherapeutic agents. , 2000, Journal of the National Cancer Institute.

[47]  K. Nicolaou,et al.  Design, synthesis, and biological properties of highly potent epothilone B analogues. , 2003, Angewandte Chemie.

[48]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[49]  A. L. Risinger,et al.  Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent , 2015, Clinical Cancer Research.

[50]  P. Kunapuli,et al.  A combination of ultrahigh throughput PathHunter and cytokine secretion assays to identify glucocorticoid receptor agonists. , 2009, Analytical biochemistry.

[51]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[52]  S. Bryant,et al.  PubChem as a public resource for drug discovery. , 2010, Drug discovery today.

[53]  E. Nogales,et al.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[55]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.